SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Heng Zhang, Li Wang, Meijie Quan, Jie Huang, Peng Wu, Qin Lu, Yongjun Fang, Health-related quality of life in children with chronic immune thrombocytopenia in China, Health and Quality of Life Outcomes, 2016, 14, 1

    CrossRef

  2. 2
    Quentin A. Hill, Adrian C. Newland, Fatigue in immune thrombocytopenia, British Journal of Haematology, 2015, 170, 2
  3. 3
    Dominik Selleslag, Robert Bird, Ivy Altomare, Aristoteles Giagounidis, Ann Janssens, Ingrid Pabinger, Vinod Pullarkat, Helen Wei, Georg Kreuzbauer, Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider, European Journal of Haematology, 2015, 94, 2
  4. 4
    A. Cuker, ITP and TTP: interpreting evidence in light of patient values, Blood, 2015, 125, 10, 1514

    CrossRef

  5. 5
    C. Neunert, N. Noroozi, G. Norman, G. R. Buchanan, J. Goy, I. Nazi, J. G. Kelton, D. M. Arnold, Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review, Journal of Thrombosis and Haemostasis, 2015, 13, 3
  6. 6
    David J. Kuter, Cynthia Macahilig, Kelly M. Grotzinger, Sara A. Poston, Peter Feng Wang, Katie L. Dawson, Melea Ward, Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim, International Journal of Hematology, 2015, 101, 3, 255

    CrossRef

  7. 7
    Nada Suvajdzic, Radmila Zivkovic, Irena Djunic, Ana Vidovic, Olivera Markovic, Dragomir Marisavljevic, Dragica Tomin, Ivo Elezovic, Tatjana Pekmezovic, Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia, Platelets, 2014, 25, 6, 467

    CrossRef

  8. 8
    Andrew Shih, Ishac Nazi, John G. Kelton, Donald M. Arnold, Novel treatments for immune thrombocytopenia, La Presse Médicale, 2014, 43, 4, e87

    CrossRef

  9. 9
    Mala Varma, Association of birthdays with distant relapses of immune thrombocytopenia, Medical Hypotheses, 2013, 80, 3, 325

    CrossRef

  10. 10
    Dawn Lee, Patrick Thornton, Alexander Hirst, Lucie Kutikova, Robert Deuson, Nic Brereton, Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland, Applied Health Economics and Health Policy, 2013, 11, 5, 457

    CrossRef

  11. 11
    John A. D’Orazio, Jessica Neely, Nina Farhoudi, ITP in Children, Journal of Pediatric Hematology/Oncology, 2013, 35, 1, 1

    CrossRef

  12. 12
    Hirokazu Kashiwagi, Yoshiaki Tomiyama, Pathophysiology and management of primary immune thrombocytopenia, International Journal of Hematology, 2013, 98, 1, 24

    CrossRef

  13. 13
    S. LAKSHMANAN, A. CUKER, Contemporary management of primary immune thrombocytopenia in adults, Journal of Thrombosis and Haemostasis, 2012, 10, 10
  14. 14
    M. Iskedjian, A. T. Tinmouth, D. M. Arnold, R. Deuson, J. J. Isitt, J. Mikhael, Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue, Journal of Medical Economics, 2012, 15, 2, 313

    CrossRef

  15. 15
    T Brown, Ruslan V Horblyuk, Kelly M Grotzinger, Axel C Matzdorff, Chris L Pashos, Patient-reported treatment burden of chronic immune thrombocytopenia therapies, BMC Blood Disorders, 2012, 12, 1, 2

    CrossRef

  16. 16
    Jenny M. Despotovic, Michele P. Lambert, Jay H. Herman, Terry B. Gernsheimer, Keith R. McCrae, Michael D. Tarantino, James B. Bussel, RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME), Transfusion, 2012, 52, 5
  17. 17
    Ann Janssens, Romiplostim for the treatment of primary immune thrombocytopenia, Expert Review of Hematology, 2012, 5, 2, 133

    CrossRef

  18. 18
    Robert Deuson, Mark Danese, Susan D. Mathias, Marieke Schoonen, Jon Fryzek, The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim, Journal of Medical Economics, 2012, 15, 5, 956

    CrossRef

  19. 19
    Miguel A. Sanz, Louis Aledort, Susan D. Mathias, Xuena Wang, John J. Isitt, Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP), Value in Health, 2011, 14, 1, 90

    CrossRef

  20. 20
    Stavroula Tsiara, Nichola Cooper, Eltrombopag for the treatment of chronic immune thrombocytopenia, Clinical Investigation, 2011, 1, 2, 295

    CrossRef

  21. 21
    Julia L. Newton, Jessica A. Reese, Shirley I. Watson, Sara K. Vesely, Paula H. B. Bolton-Maggs, James N. George, Deirdra R. Terrell, Fatigue in adult patients with primary immune thrombocytopenia, European Journal of Haematology, 2011, 86, 5
  22. 22
    Roberto Stasi, Adrian C. Newland, ITP: a historical perspective, British Journal of Haematology, 2011, 153, 4
  23. 23
    Lisa J. Toltl, Donald M. Arnold, Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters, British Journal of Haematology, 2011, 152, 1
  24. 24
    Graham Molineux, The development of romiplostim for patients with immune thrombocytopenia, Annals of the New York Academy of Sciences, 2011, 1222, 1
  25. 25
    Hannah Tamary, Jelena Roganovic, Meera Chitlur, Diane J. Nugent, Consensus Paper—ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia, Annals of Hematology, 2010, 89, S1, 5

    CrossRef

  26. 26
    Graham Molineux, Adrian Newland, Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside, British Journal of Haematology, 2010, 150, 1
  27. 27
    Thomas Kühne, Paul Imbach, Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia, Annals of Hematology, 2010, 89, S1, 67

    CrossRef

  28. 28
    Julie Blatt, Brent Weston, Stuart Gold, FATIGUE AS MARKER OF THROMBOCYTOPENIA IN CHILDHOOD IDIOPATHIC THROMBOCYTOPENIC PURPURA, Pediatric Hematology and Oncology, 2010, 27, 1, 65

    CrossRef

  29. You have free access to this content29
    Ameet Sarpatwari, Shirley Watson, Sebhat Erqou, Howard Anderson, John Grainger, Julian P. T. Higgins, Adrian C. Newland, Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP), British Journal of Haematology, 2010, 151, 2
  30. 30
    A. Cuker, D. B. Cines, Immune Thrombocytopenia, Hematology, 2010, 2010, 1, 377

    CrossRef

  31. 31
    Waleed Ghanima, Pål Holme, Geir Tjønnfjord, Immunologisk trombocytopeni - patofysiologi og behandling, Tidsskrift for Den norske legeforening, 2010, 130, 21, 2120

    CrossRef

  32. 32
    Michael D. Tarantino, Susan D. Mathias, Claire F. Snyder, John J. Isitt, Terry Gernsheimer, Joan Young, Impact of ITP on physician visits and workplace productivity, Current Medical Research and Opinion, 2010, 26, 2, 319

    CrossRef

  33. 33
    D. Provan, R. Stasi, A. C. Newland, V. S. Blanchette, P. Bolton-Maggs, J. B. Bussel, B. H. Chong, D. B. Cines, T. B. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. J. Hunt, P. A. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. A. Sanz, M. Tarantino, S. Watson, J. Young, D. J. Kuter, International consensus report on the investigation and management of primary immune thrombocytopenia, Blood, 2010, 115, 2, 168

    CrossRef

  34. 34
    Agota Szende, John Brazier, Caroline Schaefer, Robert Deuson, John J. Isitt, Paresh Vyas, Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura, Current Medical Research and Opinion, 2010, 26, 8, 1893

    CrossRef

  35. 35
    Waleed Ghanima, James B. Bussel, Thrombopoietic Agents in Immune Thrombocytopenia, Seminars in Hematology, 2010, 47, 3, 258

    CrossRef

  36. 36
    Mansoor N. Saleh, Maxine Fisher, Kelly M. Grotzinger, Analysis of the impact and burden of illness of adult chronic ITP in the US, Current Medical Research and Opinion, 2009, 25, 12, 2961

    CrossRef

  37. 37
    Jacqueline A. Guidry, James N. George, Sara K. Vesely, Shelia M. Kennison, Deirdra R. Terrell, Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives, European Journal of Haematology, 2009, 83, 3
  38. 38
    James B Bussel, Drew Provan, Tahir Shamsi, Gregory Cheng, Bethan Psaila, Lidia Kovaleva, Abdulgabar Salama, Julian M Jenkins, Debasish Roychowdhury, Bhabita Mayer, Nicole Stone, Michael Arning, Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial, The Lancet, 2009, 373, 9664, 641

    CrossRef

  39. 39
    Susan D. Mathias, Sue K. Gao, Mark Rutstein, Claire F. Snyder, Albert W. Wu, David Cella, Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences, Current Medical Research and Opinion, 2009, 25, 2, 375

    CrossRef

  40. You have free access to this content40
    Marc Michel, Immune thrombocytopenic purpura: epidemiology and implications for patients, European Journal of Haematology, 2009, 82,
  41. 41
    James N. George, Susan D. Mathias, Ronald S. Go, Matthew Guo, David H. Henry, Roger Lyons, Robert L. Redner, Lawrence Rice, Martin R. Schipperus, Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials, British Journal of Haematology, 2009, 144, 3
  42. 42
    ITP in Elderly Patients: Practicing With S. Gerald Sandler, MD, Community Oncology, 2009, 6, 12, 571

    CrossRef

  43. 43
    Donald M Arnold, Ishac Nazi, John G Kelton, New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses, Expert Opinion on Investigational Drugs, 2009, 18, 6, 805

    CrossRef

  44. 44
    Mohamed Hamidou, Qualité de vie et Purpura Thrombopénique Immunologique, La Revue de Médecine Interne, 2009, 30, 9, H6

    CrossRef

  45. 45
    Feng Xie, Gord Blackhouse, Nazila Assasi, Kaitryn Campbell, Mitchell Levin, Jim Bowen, Jean-Eric Tarride, David Pi, Ron Goeree, Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura, Clinical Therapeutics, 2009, 31, 5, 1082

    CrossRef

  46. 46
    Adrian Newland, Thrombopoietin receptor agonists in the treatment of thrombocytopenia, Current Opinion in Hematology, 2009, 16, 5, 357

    CrossRef

  47. 47
    James B. Bussel, Traditional and New Approaches to the Management of Immune Thrombocytopenia: Issues of When and Who to Treat, Hematology/Oncology Clinics of North America, 2009, 23, 6, 1329

    CrossRef

  48. 48
    Claire F. Snyder, Susan D. Mathias, David Cella, John J. Isitt, Albert W. Wu, Joan Young, Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey, Current Medical Research and Opinion, 2008, 24, 10, 2767

    CrossRef

  49. 49
    Bethan Psaila, James B. Bussel, Refractory immune thrombocytopenic purpura: current strategies for investigation and management, British Journal of Haematology, 2008, 143, 1
  50. 50
    James B. Bussel, Platelets, 2007,

    CrossRef